Having trouble viewing this email? View it in your web browser

Share this: 

October 2020  

A Letter from the President

I hope this email finds you safe and well.  

Happy (early) Halloween!  This time of year is typically when people get together.  COVID-19 has changed that up for all of us.  We hope you know our thoughts and hearts are with you, the lupus community during this difficult time.

We are getting ready to launch our Holiday Giving Campaign!  Amazon Smile is one way to shop and give.  We'll also be participating in Giving Tuesday again this year.

We know that funds are tight and are honored by any donation you may be able to give.

The RUSH Lupus Clinic & LSI Patient Education event is coming up on December 5th.  This event is virtual but we anticipate the same excellent presentations and panel discussion we have come accustomed to.  Registration is FREE and required for access information.

We are busy planning events for 2021!  Be sure that everything we offer will be safe and with the needs of the lupus community top of mind.

Together we make a difference.

Mary Dollear


A Patient Asks: What is Lupus Remission?

Medical Advisory Board members answer lupus questions.  If you have a question, please forward it to info@lupusil.org or call 312-542-0002.

Remission is defined in various ways. For lupus, we use treat to target definition of how well the disease is doing. It has four categories.


4th Annual Rush Lupus Clinic & LSI Educational Event

December 5, 2020

Getting to Know COVID 19 from a Socially Safe Distance 
Presented by: Dr. Sobia Hassan
Osteoporosis & Lupus
Presented by: Dr. Sonali Khandelwal 
Healthy Eating Including Supplements and Lupus
Presented by: Dr. Shilpa Arora
Panel Discussion with the Rush Lupus Clinic Staff

Registration FREE and REQUIRED!



Thanks to Dr. Robert Katz for referring the article below from M.D. /Alert.

Phase 3 LOTUS Trial Halts For Ustekinumab in Patients with SLE
By Dave Quaile, /alert Contributor, M.D./Alert 

Belimumab plus standard therapy was more effective for the treatment of patients with lupus nephritis compared with standard therapy alone, according to the results of a 2-year randomized trial. 

According to the study recently published in the New England Journal of Medicine, lupus nephritis affects 25% to 60% of patients with SLE and is the most common severe manifestation of SLE and a major cause of illness and death.


Head to Head: Documentary About Hair Loss
Thanks to Dr. Jolly for bringing this documentary to our attention.

Official Synopsis: The film follows women experiencing traumatic blows to their self-image after unexpectedly losing their hair due to Alopecia, Lupus, or chemotherapy. Among them is the film’s director, who sets out on a five-year journey to tell their stories while grappling with her own identity and what it means to be authentic. Although each of the women experience subsequent mental health, relationship, financial, and social impacts, they individually cope and recover from these challenges in dramatically different ways.


The LSI has led the lupus community through the COVID-19 crisis by providing expert educational information and providing factual information, including hosting 3 COVID-19 & the Lupus Community Web meetings with leading lupus doctors. You can watch the educational event below and the COVID-19 webpage here.

Click the image to access the Web Meeting with Dr. Ramsey-Goldman

Click the image to access the Web Meeting with Dr. Jolly

Click the image to access the Web Meeting with Dr. Katz


Team Gayla's Gang

Fatigue & Lupus

A major problem for people living with lupus is fatigue – chronic debilitating fatigue that significantly decreases quality of life and increases the risk of work disability.

How does someone manage fatigue?  Finding strategies that work for you and for lupus patients in general is the purpose of the Lupus Intervention Fatigue Trial (LIFT).  


RUSH Lupus Study

The study is a 24 week randomized, double-blind controlled multicenter study followed by an open label extension treatment for another 24 weeks. The purpose of this study is to determine whether the correction of the omega-3 deficiency may reduce disease activity in SLE patients.


312-542-0002 | info@lupusil.org 
Follow us!